• Error loading feed data
  • Error loading feed data


Abstracts  / Posters / Presentations


 ACR/ARP Annual Meeting

November 8 - 13, 2019

Atlanta, GA


Abstract Number: 1813      New Medications Are Needed for Children with Juvenile Idiopathic Arthritis                                     Oral Presentation: November 11, 2:30 PM - 4:00 PM


Abstract Number: 1815      Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients With Polyarticular-Course JIA: Results From Two Phase III Trials                                                                                                                                    Oral Presentation: November 11, 2:30 PM - 4:00 PM


Abstract Number: 1923      Disability and Health-Related Quality of Life Outcomes in Patients With Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials                                                 Oral Presentation: November 11, 4:30 PM - 6:00 PM


Abstract Number: 2708       Effect of Immunogenecity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials                                                                         Poster Session: November 12, 9:00 AM - 11:00 AM


Abstract Number: 2707     Improvement in Patient-Reported Outcomes in Patients Aged 2 - 5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study                                                 Poster Presentation: November 12, 9:00 AM - 11:00 AM


Abstract Number:              Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study                                                                                          Oral Presentation: November 12, 5:40 PM - 6:00 PM



October 2019 - Accelerating Drug Development for Polyarticular Juvenile Idiopathic Arthritis (pJIA). View the speaker slides and video recordings.


April 2019 - FDA approves Benlysta (belimumab) for children with lupus who are five years old or above


September 2018 - FDA approves subcutaneous formulation of ACTEMRA for systemic JIA 


Revised Common Rule: educational videos created by OHRP